Alan Menter, MD
Dr. Alan Menter is chair of research for Dermatology at Baylor Research Institute, as well as clinical professor of dermatology at the University of Texas Southwestern Medical School in Dallas. Dr. Alan Menter is a graduate of the Medical School of the University of Witwatersrand, South Africa. He completed his dermatology residency at Pretoria General Hospital at the University of Pretoria, also in South Africa, and two fellowships in London at Guy’s Hospital and St. John’s Hospital for Diseases of the Skin. A fellowship with the University of Texas Southwestern Medical Center in Dallas brought Menter to the United States. Since then, he has held several positions within the University of Texas and Baylor University systems. In 1992, he was appointed chairman of the Division of Dermatology at Baylor University Medical Center and still holds that position. In 2007, he was appointed director of the Baylor Research Center and in 2010, Program Director of the newly formed Dermatology Residency Program at Baylor University Medical Center.
Dr. Menter has a long-held interest in psoriasis and psoriatic disease research. In 1994, he co-authored the first gene discovery for psoriasis, published in Science that same year. His research on psoriasis has examined everything from ultraviolet phototherapy and biologic therapy to the mapping of genetic patterns to predict if a person is at risk of developing psoriasis. In August 2004, Dr. Menter helped found the International Psoriasis Council to raise international awareness of psoriasis as a serious autoimmune disease that can significantly impact quality of life. His clinical practice includes more than 1,600 patients on systemic and biologic therapy and phototherapy. His resume lists some 300+ articles, four books, and 19 book chapters. He serves as a member of the editorial board for several medical journals, including the Journal of Clinical Dermatology and Clinical and Experimental Dermatology. Dr. Menter has been listed in the Best Doctors in America since 1994 and Who’s Who in Medicine and Healthcare since 1996.
DISCLOSURE OF CONFLICTS OF INTEREST
Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships. The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant:
Alan Menter, MD, reported a financial interest/relationship or affiliation in the form of Advisory board: AbbVie, Amgen, Inc., Celgene Corporation, Galderma S.A., Janssen Pharmaceuticals, Inc.; Contracted research: Celgene Corporation, Eli Lilly and Company, Galderma S.A., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation; Speakers' bureau: AbbVie, Amgen, Inc., Janssen Pharmaceuticals, Inc., Pfizer, Inc.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Linda Gracie-King, MS, and Ronald Viggiani, MD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.